VYGR
Voyager Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.51
+3.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 34.5M | 40.4M | 80.0M | 250.0M | 40.9M |
| Cost of Revenue | 70.3M | 132.3M | — | 92.2M | 55.8M |
| Gross Profit | (35.9M) | (91.9M) | 80.0M | 157.8M | (14.9M) |
| Operating Expenses | |||||
| R&D Expense | 118.5M | 134.7M | 127.4M | 92.2M | 60.8M |
| SG&A Expense | 32.1M | 36.4M | 35.9M | 35.8M | 31.0M |
| General & Admin Expense | 32.1M | 36.4M | 35.9M | 35.8M | 31.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (69.2M) | (131.2M) | — | (92.2M) | (55.8M) |
| Total Operating Expenses | 81.3M | 39.9M | 163.3M | 35.8M | 36.0M |
| Cost and Expenses | 151.6M | 172.2M | 163.3M | 128.0M | 91.7M |
| Operating Income (EBIT) | (117.2M) | (131.8M) | (83.3M) | 122.0M | (50.8M) |
| Non-Operating | |||||
| Interest Income | 7.9M | 10.6M | 18.3M | 11.7M | 1.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 7.9M | 10.6M | 18.3M | 11.7M | 1.8M |
| Other Non-Op Income/Expense | 9.6M | 12.3M | 18.9M | 11.7M | 4.4M |
| Non-Operating Income (excl Interest) | (9.6M) | (12.3M) | (18.9M) | (11.7M) | (5.0M) |
| EBT (Pre-Tax Income) | (107.6M) | (119.6M) | (64.3M) | 133.7M | (46.4M) |
| Income Tax Expense | 126.0K | 144.0K | 665.0K | 1.4M | 16.0K |
| Bottom Line | |||||
| Net Income | (107.7M) | (119.7M) | (65.0M) | 132.3M | (46.4M) |
| Earnings from Cont. Ops | (107.7M) | (119.7M) | (65.0M) | 132.3M | (46.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (107.7M) | (119.7M) | (65.0M) | 132.3M | (46.4M) |
| Per Share | |||||
| Basic EPS | ($1.81) | ($2.04) | ($1.13) | $3.08 | ($1.21) |
| Diluted EPS | ($1.81) | ($2.04) | ($1.13) | $2.97 | ($1.21) |
| Revenue Per Share | $0.57 | $0.69 | $1.39 | $5.81 | $1.07 |
| Shares | |||||
| Basic Shares Outstanding | 60.5M | 58.7M | 57.7M | 43.0M | 38.4M |
| Diluted Shares Outstanding | 60.5M | 58.7M | 57.7M | 44.6M | 38.4M |
| Profitability Metrics | |||||
| EBITDA | (102.8M) | (115.5M) | (59.6M) | 138.2M | (39.6M) |
| D&A | 4.8M | 4.1M | 4.7M | 4.4M | 6.2M |
| EBIT | (107.6M) | (119.6M) | (64.3M) | 133.7M | (45.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026